The prospective exclusive license territory may be worldwide and the field of use may be limited to the use of Licensed Patent Rights for the following: “Class II or III computer-assisted diagnostics systems for use with Magnetic Resonance Imaging, of the anatomy of the prostate.”

The subject technology is an automated computer-assisted diagnostic system for processing and visualizing prostate lesions on MRI. The system uses specialized algorithms (an ensemble of multiple random decision trees, Random Forest) that is trained against: (1) Hand-drawn contours, (2) recorded biopsy results, and (3) normal cases from randomly sampled patient images weighted for lesion size. The system produces a probability map of potential cancerous lesions in multiparametric MRI.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty-bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. Complete applications for a license in the prospective field of use that are filed in response to this notice within the 15 days of this notice, will be treated as objections to the grant of the contemplated Exclusive Patent License Agreement. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.
property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Environmental Health Sciences Special Emphasis Panel; Career Development in Environmental Research.

**Date:** November 2, 2017.

**Time:** 8:30 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** NIEHS/National Institutes of Health Keystone Building, 530 Davis Drive, Research Triangle Park, NC 27709 (Virtual Meeting).

**Contact Person:** Laura A. Thomas, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, 919–541–2824, laura.thomason@nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

**Catalogue of Federal Domestic Assistance Program Nos.** 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS

**Dated:** October 20, 2017.

**Natasha M. Copeland,**

**Program Analyst, Office of the Federal Advisory Committee Policy.**

[FR Doc. 2017–23180 Filed 10–24–17; 8:45 am]

**BILLING CODE 4140–01–P**

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Government-Owned Inventions; Availability for Licensing**

**AGENCY:** National Institutes of Health.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S.

**FOR FURTHER INFORMATION CONTACT:** Licensing information and copies of the patent applications listed below may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579.

A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.

**SUPPLEMENTARY INFORMATION:** This notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. A description of the technology follows.

**Segmented Metallic Guidewires**

*Description of Technology:* The invention pertains to segmented metallic guidewires that are suitable for MRI catheterization. Guidewires contain plurality of short conductive metallic segments that are individually short enough to not resonate during MR imaging. The conductive segments are electrically insulated from each other and mechanically coupled together end-to-end via connectors, such as stiffness matched connectors, to provide a sufficiently long, strong, and flexible guidewire for catheterization that is non-resonant during MRI.

**Potential Commercial Applications:** Endovascular interventions.

**Inventors:** Robert Lederman, Ozgur Kocaturk, Burcu Basar (NHLBI).


**Licensing Contact:** Michael Shmilovich, Esq. CLP; 301–435–5019; shmilovm@nih.gov.

**Dated:** October 18, 2017.

**Michael Shmilovich,**

**Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.**

[FR Doc. 2017–23178 Filed 10–24–17; 8:45 am]

**BILLING CODE 4140–01–P**

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute on Drug Abuse; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel; Multi-